Aiforia Signed Commercial Agreement With PathAI
The deal integrates Aiforia’s AI pathology models into the PathAI AISight Marketplace for labs in Europe and the U.S.
Updated on Oct. 12, 2026 in Healthcare
Live Poll
Do you trust AI-driven tools to assist in the accuracy of medical diagnostic results?
Aiforia has entered into a commercial agreement with PathAI to distribute its digital pathology solutions. Aiforia’s AI models will now be available through the AISight Marketplace to laboratories across Europe and the United States.
Why it matters
The partnership aims to expand the accessibility of Aiforia’s AI diagnostic tools by integrating them directly into existing clinical review workflows. By utilizing the PathAI platform, laboratories can streamline their digital pathology processes.
Aiforia provides CE-IVD marked AI solutions, while the PathAI AISight Dx system holds certification for primary diagnosis in the EEA, Switzerland, and the UK. PathAI handles all contracting, billing, and support services for these integrated tools.
The players
Aiforia
This company provides AI solutions for digital pathology, including CE-IVD marked models used in European markets.
PathAI
A member of the Roche Group, this organization developed the AISight Dx Image Management System for digital pathology.
The details
Aiforia’s AI solutions are designed to be embedded directly into case review workflows within the AISight platform. This integration allows pathologists to access AI-assisted diagnostics within the same digital environment they use for primary imaging.
Timeline
Aiforia announced the commercial agreement with PathAI on October 12, 2026.
Market Landscape
The integration follows the expansion of the AISight Dx Image Management System into new global markets, marking a shift toward standardized digital pathology platforms. This move positions PathAI and Aiforia to compete more aggressively in the rapidly consolidating digital diagnostics sector.
Laboratories using the AISight platform can expect a more integrated digital workflow, as AI tools will now reside directly within their existing case review interface. PathAI will serve as the single point of contact for billing and support, simplifying the administrative requirements for participating labs.
The takeaway
This partnership highlights the growing importance of platform interoperability in medical diagnostics. Laboratories looking to implement AI should evaluate how third-party tools integrate with their current image management systems to minimize workflow disruption.
Further reading
For more on industry developments, visit the Healthcare section.
Source note: This article includes information reported by Selectscience.
Live Poll
Do you trust AI-driven tools to assist in the accuracy of medical diagnostic results?
